Correlation of high sensitivity C-reactive protein and calcific aortic valve disease

Mayo Clinic Proceedings

Volumn 82, Issue 2, 2007, Pages 171-174

  Jeevanantham, Vinodh ^a,c   Singh, Natasha ^a   Izuora, Kenneth ^a   D'Souza, John P ^b   Hsi, David H ^a  

^a UNITY HEALTH SYSTEM   (United States)

^b ACM Medical Laboratory Rochester   (United States)

^c Department of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL;

AGED; AORTA ATHEROSCLEROSIS; AORTA STENOSIS; AORTA VALVE DISEASE; ARTICLE; CALCIFIC AORTIC VALVE DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 33846660096     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.2.171     Document Type: Article

References (31)

1. Hughes BR, Chahoud G, Mehta JL. Aortic stenosis: is it simply a degenerative process or an active atherosclerotic process? Clin Cardiol. 2005;28: 111-114.
2. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111: 3316-3326.
3. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol. 1997;29:630-634.
4. Galante A, Pietroiusti A, Vellini M, et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol. 2001;38:1078-1082.
5. Agmon Y, Khandheria BK, Tajik AJ, et al. Inflammation, infection, and aortic valve sclerosis: insights from the Olmsted County (Minnesota) population. Atherosclerosis. 2004;174:337-342.
6. Gunduz H, Akdemir R, Binak E, Tamer A, Keser N, Uyan C. Can serum lipid and CRP levels predict the "severity" of aortic valve stenosis? Acta Cardiol. 2003;58:321-326.
7. Roberts WL. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: laboratory tests available to assess inflammation - performance and standardization: a background paper. Circulation. 2004;110:e572-e576.
8. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001;47:403-411.
9. Kullo IJ, Ballantyne CM. Conditional risk factors for atherosclerosis. Mayo Clin Proc. 2005;80:219-230.
10. Ursella S, Mazzone M, Portale G, et al. How to use the C-reactive protein in cardiac disease? Minerva Cardioangiol. 2005;53:59-68.
11. Torres JL, Ridker PM. High sensitivity C-reactive protein in clinical practice. Am Heart Hosp J. 2003 Summer;1:207-211.
12. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women Circulation. 2003;107:391-397.
13. Gerber IL, Stewart RA, Hammett CJ, et al. Effect of aortic valve replacement on C-reactive protein in nonrheumatic aortic stenosis. Am J Cardiol. 2003; 92:1129-1132.
14. Cosmi JE, Kort S, Tunick PA, et al. The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening. Arch Intern Med. 2002;162:2345-2347.
15. Faggiano P, Antonini-Canterin F, Erlicher A, et al. Progression of aortic valve sclerosis to aortic stenosis. Am J Cardiol. 2003;91:99-101.
16. Peltier M, Trojette F, Sarano ME, Grigioni F, Slama MA, Tribouilloy CM. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol. 2003;91:97-99.
17. Peter M, Hoffmann A, Parker C, Luscher T, Burckhardt D. Progression of aortic stenosis: role of age and concomitant coronary artery disease. Chest. 1993;103:1715-1719.
18. Pohle K, Otte M, Mäffert R, et al. Association of cardiovascular risk factors to aortic valve calcification as quantified by electron beam computed tomography. Mayo Clin Proc. 2004;79:1242-1246.
19. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
20. Pasowicz M, Konieczynska M, Podolec P, et al. Evaluation of the relationship between selected markers of the inflammatory process and aortic valve calcifications. Acta Cardiol. 2004;59:219-221.
21. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004 Mar 23;109:1349-1353. Epub 2004 Mar 15.
22. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
23. Sánchez PL, Santos JL, Kaski JC, et al, Grupo AORTICA (Grupo de Estudio de la Estenosis Aórtica). Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am J Cardiol. 2006 Jan 1;97:90-93. Epub 2005 Nov 10.
24. Guldiken S, Demir M, Arikan E, et al. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res. 2007;119:79-84. Epub 2006 Feb 14.
25. Rogowski O, Shapira I, Toker S, et al. Obesity-related correlation between C-reactive protein and the calculated 10-y Framingham Coronary Heart Disease Risk Score. Int J Obes (Lond). 2005;29:772-777.
26. Antonini-Canterin F, Popescu BA, Huang G, et al. Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? Ital Heart J. 2005;6:119-124.
27. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001;88:693-695.
28. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104:2205-2209.
29. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002;40:1723-1730.
30. Nissen SE, Tuzcu EM, Schoenhagen P, et al, Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
31. Ridker PM, Cannon CP, Morrow D, et al, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.